Literature DB >> 21210481

Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.

Ranjit Akolekar1, Argyro Syngelaki, Rita Sarquis, Mona Zvanca, Kypros H Nicolaides.   

Abstract

OBJECTIVE: To develop models for prediction of pre-eclampsia (PE) based on maternal factors and biophysical and biochemical markers at 11-13 weeks' gestation.
METHODS: Screening study of singleton pregnancies at 11-13 weeks including 752 (2.2%) that subsequently developed PE and 32,850 that were unaffected by PE. Models were developed for the prediction of early PE, requiring delivery before 34 weeks, intermediate PE with delivery at 34-37 weeks and late PE delivering after 37 weeks. The data used for the models were firstly, maternal characteristics and history, uterine artery pulsatility index, mean arterial pressure and serum pregnancy-associated plasma protein-A obtained from the screening study and secondly, maternal serum or plasma concentration of placental growth factor, placental protein-13, inhibin-A, activin-A, soluble endoglin, pentraxin-3 and P-selectin obtained from case-control studies.
RESULTS: In screening for PE by maternal factors only at a fixed false positive rate of 5%, the estimated detection rates were 33.0% for early PE, 27.8% for intermediate PE and 24.5% for late PE. The respective detection rates in screening by a combination of maternal factors, biophysical and biochemical markers were 91.0, 79.4 and 60.9%.
CONCLUSIONS: Effective prediction of PE can be achieved at 11-13 weeks' gestation.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21210481     DOI: 10.1002/pd.2660

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  85 in total

Review 1.  Extracellular nucleic acids in maternal circulation as potential biomarkers for placental insufficiency.

Authors:  Ilona Hromadnikova
Journal:  DNA Cell Biol       Date:  2012-02-24       Impact factor: 3.311

2.  Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?

Authors:  Robert W Powers; James M Roberts; Daniel A Plymire; Dominick Pucci; Saul A Datwyler; Don M Laird; David C Sogin; Arun Jeyabalan; Carl A Hubel; Robin E Gandley
Journal:  Hypertension       Date:  2012-05-29       Impact factor: 10.190

Review 3.  Molecular Mechanisms of Preeclampsia.

Authors:  Tammy Hod; Ana Sofia Cerdeira; S Ananth Karumanchi
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

4.  Preeclampsia - Aetiology, Current Diagnostics and Clinical Management, New Therapy Options and Future Perspectives.

Authors:  A-C Tallarek; B Huppertz; H Stepan
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-12       Impact factor: 2.915

5.  A description of the methods of the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b).

Authors:  David M Haas; Corette B Parker; Deborah A Wing; Samuel Parry; William A Grobman; Brian M Mercer; Hyagriv N Simhan; Matthew K Hoffman; Robert M Silver; Pathik Wadhwa; Jay D Iams; Matthew A Koch; Steve N Caritis; Ronald J Wapner; M Sean Esplin; Michal A Elovitz; Tatiana Foroud; Alan M Peaceman; George R Saade; Marian Willinger; Uma M Reddy
Journal:  Am J Obstet Gynecol       Date:  2015-01-31       Impact factor: 8.661

Review 6.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

7.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

8.  Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age.

Authors:  Liora Madar-Shapiro; Ido Karady; Alla Trahtenherts; Argryo Syngelaki; Ranjit Akolekar; Liona Poon; Ruth Cohen; Adi Sharabi-Nov; Berthold Huppertz; Marei Sammar; Kata Juhasz; Nandor Gabor Than; Zoltan Papp; Roberto Romero; Kypros H Nicolaides; Hamutal Meiri
Journal:  Fetal Diagn Ther       Date:  2017-07-21       Impact factor: 2.587

9.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

10.  First-trimester prediction of preterm birth using ADAM12, PAPP-A, uterine artery Doppler, and maternal characteristics.

Authors:  Katherine R Goetzinger; Alison G Cahill; Janet Kemna; Linda Odibo; George A Macones; Anthony O Odibo
Journal:  Prenat Diagn       Date:  2012-07-31       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.